X

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Aims to Conduct Further Human Clinical Trials Following Positive TurboCBD Results

Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP) plans to conduct additional clinical trials using DehydraTECH(TM) in CBD after recently reporting noteworthy results of cardiovascular performance improvements with TurboCBD. A recent article discussing the company reads, “TurboCBD is Lexaria’s proprietary DehydraTECH-powered, CBD-fortified hemp-oil capsule. The capsules are formulated with full-spectrum hemp oil, ginseng and ginkgo for enhanced focus and memory. They are marketed as a mental and physical boost aimed at helping to remove brain fog, fatigue and stress. TurboCBD is molecularly engineered for quick and high absorption rates into the circulatory system. . . . In a recent press release (http://ibn.fm/OwOtT), Lexaria announced that the results from a healthy-human clinical trial provided evidence that a single 90mg dose of TurboCBD resulted in lower blood pressure, higher blood flow to the brain, faster delivery onset of CBD into the bloodstream and larger quantities of CBD within the blood as compared to an equal dose of generic CBD. Due to the positive results of this study, the company plans to conduct additional human clinical trials over the course of the next year using DehydraTECH in CBD.”

To view the full article, visit http://ibn.fm/Um7RC

About Lexaria Bioscience Corp.

Lexaria Bioscience has developed and outlicenses its disruptive delivery technology that promotes healthier ingestion methods, lower overall dosing and quicker onset of lipophilic active molecules. Lexaria has 10 patents granted in the United States and Australia, and has filed over 50 patent applications worldwide across 10 patent families. Lexaria’s technology provides more rapid delivery to the bloodstream, as well as important taste-masking benefits for orally administered bioactive molecules including cannabinoids, vitamins, nonsteroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules. For more information, visit the company’s website at www.LexariaBioscience.com.

About QualityStocksNewsBreaks

QualityStocksNewsBreaks provide a rapid summary of corporate news that catch the attention of QualityStocks. QualityStocksBreaks are designed to keep investors up to date on important and breaking news in the small-cap and micro-cap markets. Spanning all industries, including energy, entertainment, telecommunications, healthcare, retail and more, these news breaks deliver opportunities the investment community may have missed. Whether it is earnings results, mergers and acquisitions, or any other market-moving news, our news breaks keep you in the know. QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential.

QualityStocks (QS)
Scottsdale, Arizona
www.qualitystocks.com
480.374.1336 Office
Editor@QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php

Related Post